Research Articles | Aplastic Anemia and MDS International Foundation (AAMDSIF)

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World Apr 2025 American Journal of Hematology Aplastic Anemia
Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database Apr 2025 Annals of Hematology Aplastic Anemia
Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria Apr 2025 Hamostaseologie Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies Apr 2025 Blood Advances Paroxysmal Nocturnal Hemoglobinuria (PNH)
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry Apr 2025 Haematologica Myelodysplastic Syndromes (MDS)
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial Apr 2025 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study Mar 2025 Blood Cancer Journal Myelodysplastic Syndromes (MDS)
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome Mar 2025 BioDrugs Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Mar 2025 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) Mar 2025 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)